{
    "root": "9fe81197-8014-4967-aa15-7525509d532c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PANTOPRAZOLE SODIUM",
    "value": "20250402",
    "ingredients": [
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        }
    ],
    "indications": "pantoprazole sodium delayed-release tablets indicated :",
    "contraindications": "* controlled extend beyond 12 months indication dose frequency short-term treatment erosive esophagitis associated gerd ( 2.1 ) adults 40 mg daily 8 weeks children ( 5 years older ) ≥ 15 kg < 40 kg 20 mg daily 8 weeks ≥ 40 kg 40 mg maintenance healing erosive esophagitis ( 2.1 ) adults 40 mg daily * pathological hypersecretory conditions including zollinger-ellison syndrome ( 2.1 ) adults 40 mg twice daily full prescribing information instructions",
    "warningsAndPrecautions": "supplied pantoprazole sodium delayed-release tablets usp , 20 mg supplied yellow colored , round shaped tablets imprinted '52 ' black ink one side plain side . tablets supplied bottles : bottles 90 tablets child-resistant closure ndc 64980-676-09 pantoprazole sodium delayed-release tablets usp , 40 mg supplied yellow colored , oval shaped biconvex tablets imprinted '53 ' black ink one side plain side . tablets supplied bottles : bottles 90 tablets child-resistant closure ndc 64980-677-09 bottles 1,000 tablets ndc 64980-677-10 storage store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "pantoprazole sodium contraindicated patients known hypersensitivity component formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . proton pump inhibitors ( ppis ) , including pantoprazole sodium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole sodium delayed-release tablets are indicated for:",
    "contraindications_original": "*Controlled studies did not extend beyond 12 months Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 weeks Children (5 years and older) ≥ 15 kg to < 40 kg 20 mg Once Daily for up to 8 weeks ≥ 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily See full prescribing information for administration instructions",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Pantoprazole sodium delayed-release tablets USP, 20 mg are supplied as yellow colored, round shaped tablets imprinted with '52' in black ink on one side and plain on the other side.\n                  Tablets are supplied in bottles of:\n                  Bottles of 90 Tablets with child-resistant closure NDC 64980-676-09\n                  Pantoprazole sodium delayed-release tablets USP, 40 mg are supplied as yellow colored, oval shaped biconvex tablets imprinted with '53' in black ink on one side and plain on the other side.\n                  Tablets are supplied in bottles of:\n                  Bottles of 90 Tablets with child-resistant closure NDC 64980-677-09\n                  Bottles of 1,000 Tablets                                         NDC 64980-677-10\n                  \n                     Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6)].\n                     \n                     Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]."
}